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Objectives. The aim of the study was t •a prospectively estimate
the safety of thrombolytic therapy in elderly patients with massive
pulmonary embolism In comparison with that in nonelderly
patients.
Background. In massive pulmonary embolism, lysis of thrombi
can be achieved faster with thrombolytic therapy than with
conventional beparin therapy, but it is administered with great
caution in elderly patients because the risk of bleeding is thought
to be higher than in nonelderly patients . Yet, thrombolytic
therapy might be of value an elderly patients also, in allowing
potentially more rapid improvement than is achieved with con-
ventional heparin therapy
.
Methods . Eighty-nine patients with massive pulmonary embo-
lism defined as Miller score ?17134 underwent thrombolytic
therapy without consideration of age if they had no contraindica-
tion for such treatment. Fifty-three patients were s70 years old
(mean age = SD 54 = 15 years; range 18 to 70), and 36 patients
were L-71 years old (78 # 5 years; range 71 to 88) . Except for
mean age, there were no significant differences between the two
treatment groups, particularly in terms of clinical presentation,
average Miller score and pulmonary artery pressure regimen .
Thrombolytic therapy was administered in the form of streptoki-
nose at a dose of 100,000 IUOh over 12 h, with an initial injection
of 250,000 IU over 15 min . Heparin was introduced 12 h after
initiation of thrombolytic therapy . Urokinase or tissue-type plas-
minogen activator was used only in case of contraindication to
streptokinase.
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Since publication of the results of the Urokinase Pulmonary
Embolism Trial (1) and the Urokinase-Streptokinase Pulmo-
nary Embolism Trial (2), it has been known that in massive
pulmonary embolism, lysis of thrombi can be achieved faster
with thrombolytic therapy than with conventional heparin
therapy. Urokinase and, to a lesser extent, streptokinase
have been in wide clinical use ever since (3-10) . Recently,
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Results . The frequency of uncomplicated clinical course was
the same in both treatment groups . Surgical embolectomy was
necessary in three nonelderly patients (5 .6 ) and one elderly
patient (2 .7%), Changes in pulmonary pressure regimen and
Miller score were identical in both groups . Three patients
died during the in-hospital course : two nonelderly patients
(3.7%) and one elderly patient (2 .7%). Minor bleeding occurred
in five nonelderly (9.4%) and five elderly (13 .8%) patients (p =
0.74). Major bleeding was observed in three nonelderly (5 .6%)
and five elderly (13.8%) patients (p = 0 .29). Bleeding subsequent
to early invasive procedure accounted for six (75%) of eight
patients with major bleeding: two nonelderly patients (one of
whom died) and four elderly patients . No intracranial hemorrhage
was observed . No predisposing factor for bleeding was identified,
except the need for early vascular access for pulmonary angiog-
raphy through the femoral approach or for percutaneous insertion
of an intracaval device for partial interruption of the inferior vena
cava.
Conclusions. Thrombolytic therapy administered for massive
pulmonary embolism in patients free of contraindication yields
similar results and carries a similar risk for bleeding complica-
tions in elderly compared with nonelderly patients. Limiting early
invasive procedures may result in less frequent major bleeding
complications .
(J Am Coll Cardiol 1993;22 :1075-9)
the possible advantages of recombinant tissue-type plasmin-
ogen activator (rt-PA) have been tested in several trials that
have all confirmed the efficacy of this thrombolytic agent in
pulmonary perfusion as well as in the decrease of pulmonary
resistance (11-18). However, thrombolytic therapy is admin-
istered with great caution in elderly patients because it is
thought that in these patients the risk of bleeding is higher
than in nonelderly patients (19-24) . Yet, thrombolytic ther-
apy might also be of value in elderly patients, favoring more
rapid improvement. Therefore, the aim of our study was to
prospectively estimate the safety of thrombolytic therapy in
elderly compared with nonelderly patients with massive
pulmonary embolism .
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Methods
Selection of
patients. Any patient >18 years old referred
to our institution for symptoms suggestive of massive pul-
monary embolism was considered for entry into the study
regardless of age at admission . After routine clinical exam-
ination, chest radiography, gasometry, electrocardiography
and echocardiography, patients were referred to the cathe-
terization laboratory for pulmonary angiography . Patients
were considered for thrombolytic therapy if the Miller score
was a' 7134 regardless of pulmonary pressure regimen and
clinical presentation .
Exclusion criteria were 1) significant preexisting cardiac
or pulmonary disease ; 2) recent puncture of a noncompress-
ible vessel or organ biopsy ; 3) application of a vena cava
filter or current treatment with coumarin ; 4) recent preg-
nancy or lactation ; 5) recent head trauma or cerebrovascular
accident in the previous 6 months ; 6) history of cerebral
hemorrhage on intracranial or intraspinal surgery; 7) bleed-
ing disorder or platelet count
<100,000
mm3 at admission ;
8) ptoliferative or hemorrhagic diabetic retinopathy ; 9) sys-
tolic blood pressure > 180 mm Hg or diastolic blood pressure
>110 mm Hg, or both ; 10) known dissecting or other
aneurysms ; 11) major surgery or trauma in the previous 10
days: 12) known pericarditis or endocarditis ; 13) occurrence
of allergic reactions, severe hypotension or cardiac arrest
during initial pulmonary angiography ; and 14) previous
thrombolytic therapy for the same pulmonary embolism .
Pulmonary angiography . A selective bilateral angiogram
was obtained, preferably through the brachial venous ac-
cess, before initiation of thrombolytic treatment . The coded
angiograms were reviewed by a panel of two experienced
readers unaware of the chronologic order of the angiograms
and study treatment. Severity of embolism was assessed by
the method of Miller et al . (6) . The individually allocated
scores were reviewed by the panel, and a consensus score
was derived
. Changes in pulmonary pressure were recorded
before every two pulmonary angiographic studies but were
not monitored during thrombolytic therapy.
Thrombolytic therapy. After informed consent, patients
underwent thrombolytic therapy with streptokinase or uroki-
nase. Streptokinase was injected at a dose of 250,000 lU
over 15 min, followed by a standard dose of 100,000 IU/h
over 12 h . Urokinase was used only in case of contramdica-
lion to streptokinase, at a dose of 4,400 IUiltg body weight
per h over 12 h after an initial bolus injection of 4,400 IU/kg.
In both treatment groups, heparin was introduced 12 h after
initiation of thrombolytic therapy at an initial dose of
200 lU/kg over 12 h and adapted thereafter to maintain an
activated partial thromboplastin time of two to three times
control values .
Oral anticoagulant therapy was introduced
on day 5
. Patients were followed up at least to day 10 and
were then discharged from the hospital
. Bilateral lower limb
venography was performed in every patient either immedi-
ately after pulmonary angiography or after completion of
thrombolytic therapy
. Partial interruption of the inferior
vena was carried out by means of a Greenfield filter in the
case of contraindication to long-term anticoagulant therapy
or extensive lower limb thrombosis with an upper limit of
clot reaching the inferior vena cava, or both, and in every
patient with surgical pulmonary embolectomy .
Hematologic and hemostatic measurements . Blood sam-
ples for determination of blood cell counts., hemoglobin and
plasma fibrinogen were taken before thrombolytic treatment
and 12, 24 and 48 h and 10 to 14 days thereafter . Activated
partial thromboplastin time assessment was used to monitor
heparin therapy, with target values from two to three times
control values .
Adverse events . Adverse events were noted throughout
the hospital stay . Specifically, the following bleeding com-
plications were recorded: hemorrhagic stroke confirmed by
computed tomography ; hematomas >5 cm in diameter and
prolonged external bleeding at puncture sites ; retroperito-
neal, gastrointestinal, mediastinal, pleural, pericardial and
gingival bleeding ; hemoptysis ; epistaxis ; and hematuria.
Blood transfusion and the need for surgery or any other
special measure to control bleeding were also recorded .
Major bleeding was prospectively defined as bleeding that
required blood transfusion, surgical control or discontinua-
tion of the study treatment ; bleeding causing a decrease in
hemoglobin a5 g/dl ; and hemorrhagic stroke confirmed by
computed tomography or autopsy .
Statistical analysis . All results were expressed as mean
value ± SD . Categoric data analyses were performed with
chi-square analysis and Fisher exact tests. Comparison of
continuous data between both groups was performed using
the unpaired Student t test. Multiple logistic regression
analysis for prediction of bleeding complications was also
performed in the entire study population using the following
variables: age, gender, weight, history of systemic hyperten-
sion, history of diabetes mellitus, venous access for pulmo-
nary angiography and insertion of intracaval device, fibrin-
ogen level and activated partial thromboplastin time values .
A p value < 0.05 was considered significant . All reported
p values are two sided .
Results
Study patients (Table 1) . From June 1988 to February
1992, 89 patients were enrolled in the study, 53 patients X70
years (nonelderly group: mean age ± SD 54 # 15 years,
range 18 to 70) and 36 patients ?71 years (elderly group:
mean age ± SD 78 ± 5 years, range 71 to 88). Except for
mean age, there were no significant differences between the
two treatment groups, particularly in terms of clinical pre-
sentation, Miller score, pulmonary artery pressure regimen
and type of thrombolytic therapy .
Clinical course (Table 2). The frequency of uncompli-
cated clinical course was the same in the two treatment
groups . The duration of hospital stay, although slightly
longer in the elderly than in the nonelderly patients, was not
significantly different in the two treatment groups . Changes
JACC Vol
. 22
. No. 4
October 1993 : 1075-9
Table 1 . Clinical Characteristics of the Study Population
Values presented are mean value
±
SD or number of patients . Dyspnea =
dyspnea functional class IV at admission; F
T
female; M = male ; Miller
(134) = Miller score
; MPA = mean pulmonary
artery pressure .
in pulmonary pressure and Miller score were identical in
both groups . Partial interruption of the inferior vena cava
was carried out in 25 patients : 10 nonelderly patients (19%a)
and 15 elderly patients (42%) (p = 0 .03) .
Three patients died during the in-hospital course : two
nonelderly patients (3.7%) and one elderly patient (2.7%)
(p = NS) . Death was due to recurrent pulmonary embolism
(one patient in each group) and to retroperitoneal bleeding
that occurred after partial interruption of the inferior vena
cava (one nonelderly patient) . Recurrence of pulmonary
embolism within the duration of thrombolytic therapy oc-
curred in one nonelderly patient (1 .8%0) who died despite
emergency surgical embolectomy and one elderly patient
(2.7%) who also died within a few minutes in intractable
cardiovascular shock . Lack of clinical and hemodynamic
improvement during thrombolytic therapy led to surgical
embolectomy in two nonelderly patients (3.8%) and one
elderly patient (2.7%) .
Bleeding complications (Table 3). Eight nonelderly (15%)
and 10 elderly patients (28%) had bleeding complications
(p = 0 .14). No intracranial bleeding occurred in either group .
Minor bleeding, limited to hematoma at the puncture site,
was observed in five nonelderly (9 .4%) and five elderly
patients (13.8%) (p = 0.74 and p = NS, respectively) . Major
Table 2 . Clinical Course After Thrombolytic Therapy
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Values presented are mean value ± SD or number
(%)
of patients
.
Abbreviations as in Table 1 .
Table 3
. Bleeding Complications
p Value
0.14
0.74
0.29
NS
NS
NS
*Hematomas linked to femoral access . Values presented are number (%)
of patients.
bleeding, as previously defined, was observed in three
nonelderly (5 .6%) and five elderly (13 .8%) patients (p = 0.29
and p = NS, respectively) . All eight patients had received
streptokinase. In each case bleeding occurred within the 1st
5 days when the patients were receiving heparin therapy, at
which time the fibrinogen level had increased to >1 g/liter in
all eight . Visceral bleeding in the form of gastrointestinal
bleeding uLc'lrred in only two patients (one in each group) .
Hematoma directly related to early invasive procedures
occurred in six patients (two nonelderly and four elderly) :
groin hematoma at the puncture site for pulmonary angiog-
raphy in two elderly patients and after partial interruption of
the inferior vena cava in two nonelderly and two elderly
patients . Surgical control of hematoma was required in four
patients (two nonelderly and two elderly patients).
In all, 16 (89%) of 18 of the overall hemorrhagic compli-
cations were observed at puncture sites, and 6 (75%) of 8 of
the instances of major bleeding were related to an early
invasive procedure-either pulmonary angiography through
femoral access or partial interruption of the inferior vena
cava. Multiple logistic regression analysis for the entire
study group revealed that neither clinical variables (age,
gender, weight, previous hypertension, diabetes mellitus)
nor biologic variables (fibrinogen level, activated partial
thromboplastin time values) were identified as independent
predictors of bleeding complications . The only predisposing
factor for bleeding was the need for early vascular access for
pulmonary angiography through .he femoral approach or for
percutaneous insertion of an it tra caval device for partial
interruption of the inferior ve .~a cava . It was therefore,
decided to modify the managen .ent policy of patients sus-
pected of having massive puln,,mnary embolism and, as a
result, to stop inclusions in the i rial .
Hematologic measurements . The magnitude of decrease
in hemoglobin level was the same in both treatment groups
(13.8 ± 2.0 to 12.4 ± 1 .9 g1100 ml in nonelderly vs . 14.0 ± 1
.9
to 12.1 ± 2.5 g/100 ml in elderly patients)
.
Discussion
This trial was undertaken because to our knowledge the
problem of thrombolytic therapy in pulmonary embolism in
Nonelderly
(<_70 yr)
(n - 53)
Elderly
(>70 yr)
(n = 36) p Value
MIF 33120 16120
0 .09
Age (yr) 54 ± 15.0 77.7 ± 5 .0 0 .01
Syncope it 10 NS
Dyspnea
27 25 NS
Shock 2 4
NS
MPA (mm Hg) 34 ± 12 .0 35 ± 9.0 NS
Miller (/34) 22 ± 3 .7 23 ± 3 .5 NS
Streptokinase therapy 45 31 NS
Urokinase therapy
8
5 NS
Nonelderly
(-<_70 yr)
Elderly
(>70 yr)
p Value
Uncomplicated course 42(79) 24(67)
Death 2(3 .7) 1(2
.7) NS
Recurrence
Embolectomy
I (fatal) (1 .8)
3(5 .6)
I (fatal) (2
.7)
1(2.7)
NS
NS
Filter insertion 10(19) 1502)
0 .03
Bleeding 8 (1 fatal) 10 NS
Hospital stay (days) I IA ± 4 .5 13 ± 5.7 NS
MPA (mm Hg)
13 ± 9 13 ± 10
NS
Miller (/34) 8 ± 2 .1 7 .3 *_ 4 NS
N;+nelderly
('-70
yr)
Elderly
(>70 yr)
Total
805)
10(28)
Minor
5(9.4) 5(13 .8)
Major
3(5.6)
5(13.8)
Cerebral
0 0
Gastrointestinal
I I
Hematoma 0
2*
Due to filter insertion
2 (1 fatal) 2
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elderly patients had not been specifically addressed previ-
ously
. The purpose of this study was therefore to prospec-
tively assess the safety of thrombolytic therapy in elderly
patients with massive pulm wary embolism compared with
nonelderly patients .
1l adolto of the study. This was not a randomized
study. It would have been more appropriate to compare two
groups of elderly patients randomly allocated to either
conventional heparin therapy or thrombolytic therapy . How-
ever, when such comparisons have been performed in the
past, nonelderly patients have all demonstrated the superior
efficacy of thrombolytic therapy on pulmonary perfusion or
on decrease in pulmonary resistance, or both (6,16,25) .
Furthermore, although no data support the idea that throm-
bolytic therapy can reduce mortality rate in massive pulmo-
nary embolism compared with conventional heparin ther-
apy, it is the policy in our institution to administer
thrombolytic therapy to those patients with massive pulmo-
nary embolism, as defined by a Miller score X17134. There-
fore, it seemed logical to compare the safety of thrombolytic
therapy between elderly and nonelderly patients when no
contraindication to thrombolytic therapy was noted at ad-
mission because the real problem is to evaluate the potential
for excess bleeding in elderly compared with nonelderly
patients .
Clinical course during throatbolytic therapy . The fre-
quency of an uncomplicated course, the need for emergency
surgical embolectomy and the rate of recurrence was the
same in both groups. Changes in pulmonary artery pressure
and pulmonary perfusion, as estimated by Miller score, were
similar in both groups. The mortality rate was not signifi-
cantly different between the two groups. In previous studies,
the mortality rate varied from 3% to 10% regardless of the
thrombolytic agent. in the Urokinase Pulmonary Embolism
Trial= (1) and the Urokinase-Streptokinase Pulmonary Embo-
lism
Trial (2), the mortality rate was 9 .2% in the streptoki-
nase group and 8.6% in the urokinase group (1,2). In more
recent reports, with rt-PA, the mortality rate was similar (3%
to 9%) (12-17,18) .
Safety. Actually, the major concern with thrombolytic
therapy in the elderly is the potential for more frequent
bleeding complications. Most of the available data referring
to this issue are drawn from trials conducted for acute
myocardial infarction, where the duration of thrombolytic
therapy and the dose of thrombolytic agent greatly differ
from those used in pulmonary embolism, so that it is not
clear whether these data can apply to pulmonary embolism .
Several clinical variables, including oral anticoagulant ther-
apy before admission, high blood pressure at admission,
body weight <70 kg, female gender, diabetes melitus and
concomitant heparin therapy, have been identified as risk
factors for excess bleeding during thrombolytic therapy
(19-24). Older age has been considered to be a predisposing
factor for bleeding by Chaitman et al . (20), who determined
that patients >70 years old have 2
.8 times more chance of
major bleeding than do patients <65 years old
. Similarly,
De Jaegere et al . (21), in 2,469 consecutive patients, and
other investigators in smaller series (11,23,24), also deter-
mined that older age was a predisposing; factor for bleeding .
In contrast, older age was not considered a specific risk
factor by Califf et at. (26). Similarly, in the International
Study of Infarct Survival and Gruppo Italiano per lo Studio
della Streptochinasi Nell' infarto Miocardico trials, the fre-
quency of bleeding was not considered significantly higher in
elderly than in nonelderly patients (27-32) .
Various and confiiaing bleeding rates have been reported
in massive pulmonary embolism (16% to 82% for overall
bleeding and 8% to 10% for major bleeding), depending on
how bleeding is defined (33). In this study, the overall as well
as the major bleeding rates tended to be lower than those
reported in previous studies . Moreover, although higher in
elderly than in nonelderly patients, bleeding rates were not
significantly different between the two groups. With an
anticipated major bleeding complication rate of 10% in
nonelderly patients, we had postulated that at least a tripling
of the rate in elderly patients would represent a clinically
meaningful excess of bleeding . Given the size of the trial, the
statistical power of the study is clearly insufficient to detect
such a difference. The minimal difference in bleeding rate
that can be detected as significant (alpha = 0 .05, beta = 0.20)
is 25% for overall bleeding and 21% for major bleeding . A
sample size of 170 patients in each group would have been
required to demonstrate that the observed differences in
major bleeding (120 for overall bleeding) was statistically
significant. Such a sample size would have meant that the
inclusion period in the study be prolonged for many more
months or years without proving that the differences, even if
shown to be significant, were clinically relevant .
Indeed, at interim analysis, multiple logistic regression
analysis clearly showed that the only predictor of bleeding,
particularly major bleeding, was the need for early vascular
access either for pulmonary angiography through the femo-
ral approach or for percutaneous insertion of an intracaval
device for partial interruption of the inferior vena cava . No
other predisposing factor was identified ; age, gender, weight
or any other variable tested was not found to be predictive of
bleeding. This observation is in keeping with previous re-
ports; major bleeding complications in pulmonary embolism
submitted to thrombolytic therapy were shown to occur
most of the time at puncture sites (34) . In light of these
observations, it appeared that prolongation of the study with
management policy grounded on early invasive diagnostic
and therapeutic procedures, as mentioned previously, would
be unnecessarily harmful and that the inclusions should be
stopped. Since then, the management policy of patients
suspected of having or proved to have a massive pulmonary
embolism was modified. Vascular access through the bra-
chial approach for pulmonary angiography was preferred
over femoral access, and indications for partial interruption
of the inferior vena cava were restricted to patients with
absolute contraindication to long-term anticoagulant therapy
and to patients undergoing surgical embolectomy. Whether
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these modifications in diagnostic and therapeutic policies
will result in less bleeding without compromising diagnostic
accuracy and without increasing the frequency of recurrent
pulmonary embolism remains to be determined .
Implications. Thrombolytic therapy appears to be a rea-
sonable therapeutic approach in elderly patients with mas-
sive pulmonary embolism, after careful search for contrain-
dications to such therapy ; but early invasive procedures
should be considered with caution . Partial interruption of the
inferior vena cava and pulmonary angiography through the
femoral approach, even though the vascular access is venous
and not arterial, carry a high risk for excess bleeding .
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